An artificial intelligence (AI)-driven screening tool successfully identified hospitalized adults at risk for opioid use ...

T-Hub and Atal Innovation Mission have selected 20 startups from over 209 applications for the fifth cohort of AIC T-Hub ...

The global drug discovery enzymes market is poised for significant expansion, projected to grow from USD 932.4 million in 2023 to USD 1,751.3 million by 2033, advancing at a compound annual growth ...

Leading artificial intelligence (AI) driven drug discovery and bioinformatics, Dr. Sita Sirisha Madugula is making ...

A multicenter study led by Cedars-Sinai created a database of adverse medication events—the fourth leading cause of death in ...

Recursion Pharmaceuticals—a relatively small company backed by the chip giant Nvidia—is betting that its massive ...

The Icahn School of Medicine at Mount Sinai has launched the AI Small Molecule Drug Discovery Center, a bold endeavor that harnesses artificial intelligence (AI) to revolutionize drug development.

The new center will design novel drug-like molecules using generative AI and optimize existing compounds to enhance their ...

Dolsten brings decades of experience in drug development and investment, having played a key role in Pfizer's industry-leading R&D efforts, including the rapid development of the COVID-19 vaccine, the ...

To stay competitive, investors should engage with continual learning tools, such as AI investment-focused newsletters, seminars, and think tanks. Similarly, venture capital related to AI startups will ...

The rise of AI is transforming workplaces across the globe, giving birth to a new category of high-performing ...